INTRODUCTION
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency was first identified in American blacks in the course of studies of sensitivity to the haemolytic effect of primaquine. [1] G-6-PD deficiency is an asymptomatic X-linked inherited condition which is almost unknown to the public. G-6-PD deficiency is produced by mutations in the G-6-PD gene, mostly point mutations and small deletions that causes structural defects in the enzyme. [2] This gene is located near the telomeric region of the long arm of the X chromosome (band Xq28), close to the genes for coagulation Factor 8, color blindness and X-linked dyskeratosis congenita. [3, 4] In relation to the red blood cell, G-6-PD functions to reduce nicotinamide adenine dinucleotide phosphate (NADPH) while oxidizing glucose-6-phosphate. NADPH is needed for the production of reduced glutathione (GSH) which is important to defend the red cells against oxidant stress.
[5] G-6-PD deficiency is the most common human enzyme defect, being present in more than 400 million people worldwide. [6] The highest prevalence is reported in Africa, Mediterranean Europe, South-East Asia, and Latin America. [7] In Nigeria, 4-26% prevalence of G-6-PD deficiency was reported. [8] Omisakin et al. [9] reported 25.5% among blood donors in the South Western part of Nigeria.
The clinical manifestations of G-6-PD deficiency contribute to neonatal jaundice which is accompanied by hyperbilirubinaemia and puts many infants at risk of brain damage (kernicterus) within the first few days of life. [10] Kernicterus can lead to hearing deficits, behavior problems, and permanent neurologic damage. [10] During childhood, many children with G-6-PD deficiency are healthy until they are exposed to a pro-oxidant medication or chemical. [10] Classically, anti-malarial drugs are strong oxidant agents and have substantial use in Sub-Saharan Africa. [10] Additionally, exposure to the pro-oxidant naphthalene, the active ingredient in mothballs, is common among young children. [10] In G-6-PD deficient children, pro-oxidant exposure can lead to a rapid imbalance in the redox status in red blood cells leading to haemolysis and resultant severe anaemia, heart failure, and even death if not recognized early. [10] The WHO recommends population screening in regions where the prevalence of G-6-PD deficiency is 3-5% or more, [11] but this has yet to become routine practice in many parts of Nigeria. Barriers to screening include cost, under-estimation of the public health impact of G-6-PD deficiency by the medical community, lack of awareness of G-6-PD deficiency among lay people and a paucity of guidelines regarding which high risk groups should be preferentially screened when general population screening is not possible. [10] Screening test for the detection of G-6-PD deficiency is a pre-requisite test for oversea travelling, especially to Mediterranean countries where fava bean is been frequently cultivated and ingested. Also before primaquine therapy when travelling from a malaria endemic to non-malaria endemic region to achieve radical cure for the relapsing liver stages of Plasmodium vivax-hypnozoites which become dormant in infected hepatocytes. [12] Several diagnostic tests methods have been used to detect G-6-PD deficiency. The fluorescent spot test is simple and cheap and has a sensitivity of 100% in homozygotes and hemizygotes. [13] A disadvantage of the test is that it only identifies individuals with less than 20% G-6-PD activity. [13] This can yield false normal results in female heterozygotes and in deficient individuals who have experienced a recent episode of hemolysis due to the elevated G-6-PD activity in reticulocytes. [14] The spot test is not well-suited for screening of neonates due to the presence of reticulocytosis. [14] Cytochemical and spectrophotometric assays are available options. The spectrophotometric assay relies on the same principles as the fluorescent spot test. [13] [14] It also requires more training and equipment than the spot test. [13] In the cytochemical assay, G-6-PD activity causes staining of individual erythrocytes by converting a water-soluble colorless compound into its insoluble dark-colored form through the production of NADPH. [14] This test has a sensitivity of 85% in heterozygotes (compared to 32% and 11% for the fluorescent spot test and spectrophotometric assay respectively). [13] The major setbacks of this test are that is it time-consuming, technically difficult and considerably more expensive than the fluorescent spot test. [14] Study by Aaron [15] has shown that, G-6-PD deficiency is implicated in the pathogenesis of a number of common diseases like hypertension, diabetes mellitus and atherosclerosis. In addition, G-6-PD deficiency could lead to hyperglycemia, making more glucose available for the non-enzymatic production of advanced glycosylation end (AGE) products and cardiac dysfunction might also be aggravated by a deficiency in G-6-PD. [16] Association of G-6-PD deficiency with cancer, cataract formation and some other disorders has also been reported with controversial results. [6, [17] [18] [19] [20] Cardiac dysfunction might also be aggravated by a deficiency in G-6-PD. As G-6-PD is a critical antioxidant enzyme, essential for maintenance of cytosolic redox status in cardiomyocytes, deficiencies may contribute to cardiac dysfunction through increased susceptibility to free radical injury and impairment of intracellular calcium transport. [21] Complete deficiency of the enzyme in leukocytes was reported to be associated with chronic granulomatous disease due to neutrophil dysfunction. [22] [23] [24] G-6-PD deficiency is the most common genetic defect of red blood cells which cannot be reversed, but its awareness allows those affected and their parents to take steps to reduce the risk of acute hemolysis. Hence, this study was undertaken to assess public awareness of G-6-PD deficiency with expectations that would probably enhance it screening beforehand thereby reducing its implications particularly in this locality.
METHODOLOGY
This is a descriptive, cross sectional survey that was conducted among people living within the metropolitan city of Sokoto. The study was approved by the ethical committee of Sokoto State Ministry of Health. The participants comprised of five hundred individuals (307 males and 193 females). All participants were briefed about the purpose of the study and informed consent was obtained from each of them. The data instrument used was interviewer-administered, semi-structured questionnaire containing close-ended questions. The first part of the questionnaire included personal information while general questions on the research topic formed the second part. The data tool was validated for errors before they were used for data collection.
Statistical analysis
The data obtained were manually edited for errors and entered for analysis using SPSS software package (Version 20). Descriptive statistics were used for all variables. Table 1 shows the demographic characteristics of participants. Males constituted the majority being 61.4% and 39.6% were females respectively. Most respondents were within the age of 20 to 29 years. On marital status, more than two-third (370; 74%), were single while less than one-third (130; 26%) were married. Occupational status of respondents shows that (363; 72.6%), (122; 24.4%) and (15; 3%) were students, civil servant and others respectively. Respondents of Hausa ethnicity made up the largest group (280; 56%) followed by those Yoruba descent (113; 22.6%), others (73; 14.6%) and those of Igbo (34; 6.8%) ethnicity. The results in figure 1 indicated that majority of the respondents are aware of the disease, and had recognized it as a blood disease. Similarly, their G-6-PD status was not known to them. Response to general knowledge questions about G-6-PD deficiency separated by gender is shown in figure 2 . The results show that males are more knowledgeable of this disease which mainly affects them.
RESULTS

DISCUSSION
Nigeria is endemic for malaria and antimalarial drugs are routinely prescribed for most cases. This treatment can induce oxidative damage to the cells and in turn causes severe haemolysis in G-6-PD deficient individual. Awareness and knowledge of this genetic condition have tremendous health benefit in the management of deficient patients. In this study, participants showed poor knowledge to basic questions about G-6-PD deficiency, though many have heard and recognized it as blood related disease. However, their knowledge about the pattern of inheritance seems to be lacking. This finding is consistent with the report of Uzoegwu and Awah [25] in Cameroon but at variance with the report of Shaikha and Amani [26] in Bahrain. These differences may be due to lack of public enlightenment education at various level on the implications of G-6-PD deficiency and compulsory screening of the disease right from birth in most part of the developing countries. 1=Have you heard of G-6-PD deficiency, 2=G-6-PD deficiency is a red cell disorder, 3= G-6-PD deficiency is an inherited disorder, 4=If a father is G-6-PD deficient and the mother is not, having a girl who is a carrier is possible, 5= Can I donate blood if am G-6-PD deficient, 6= Do you know your G-6-PD status, 7= Do you want know your status, 8= Can Fava beans trigger hemolytic episode due to G-6-PD deficiency, 9=Can antimalarial drugs trigger hemolytic episode due to G-6-PD deficiency, 10= Jaundice can be a sign of red blood cell destruction due to G-6-PD deficiency, 11= G-6-PD deficient individuals are less prone to severe malarial infection. A greater proportion of respondents did not know whether deficient individual could donate blood or not. Conversely, transfusion with G-6-PD-deficient blood carries a potential risk of haemolytic complications, especially if it is used for exchanged blood transfusion in neonates. [27] Similarly, the use of G-6-PDdeficient blood has been studied for simple and exchange transfusions. [28] It has been proposed that several biochemical changes and depletion in the antioxidant defense system occur on storage of G-6-PD-deficient blood. [28] This is likely the reasons why authors reveal the necessity of including G-6-PD testing in the blood donors screening criteria since the ultimate goal of transfusion is to benefit the recipients. [29] In the present study, almost all the respondents among which are medical personnel and students were ignorant of their G-6-PD status. As at the time of the study, there are two major hospitals in the town, neither of which routinely screen for G-6-PD deficiency which may contribute to this. The respondents showed fair knowledge of the symptoms of G-6-PD deficiency. This can be attributed to the relatively mild clinical nature of G-6-PD deficiency. No specific studies have assessed the knowledge of G-6-PD deficiency within the country to compare our results with.
CONCLUSION
We found a poor level of awareness of G-6-PD deficiency in our study. Therefore, we recommend public enlightenment programs towards ensuring G-6-PD screening beforehand to avert acute haemolytic episode which may occur in deficient individuals ignorantly treated with oxidants agents.
